The ubiquitin ligase tripartite-motif-protein 32 is induced in Duchenne muscular dystrophy

Stefania Assereto, Rosanna Piccirillo, Serena Baratto, Paolo Scudieri, Chiara Fiorillo, Manuela Massacesi, M. Traverso, Luis Juan V Galietta, Claudio Bruno, Carlo Minetti, Federico Zara, Elisabetta Gazzerro

Research output: Contribution to journalArticle

Abstract

Activation of the proteasome pathway is one of the secondary processes of cell damage, which ultimately lead to muscle degeneration and necrosis in Duchenne muscular dystrophy (DMD). In mdx mice, the proteasome inhibitor bortezomib up-regulates the membrane expression of members of the dystrophin complex and reduces the inflammatory reaction. However, chronic inhibition of the 26S proteasome may be toxic, as indicated by the systemic side-effects caused by this drug. Therefore, we sought to determine the components of the ubiquitin-proteasome pathway that are specifically activated in human dystrophin-deficient muscles. The analysis of a cohort of patients with genetically determined DMD or Becker muscular dystrophy (BMD) unveiled a selective up-regulation of the ubiquitin ligase tripartite motif-containing protein 32 (TRIM32). The induction of TRIM32 was due to a transcriptional effect and it correlated with disease severity in BMD patients. In contrast, atrogin1 and muscle RING-finger protein-1 (MuRF-1), which are strongly increased in distinct types of muscular atrophy, were not affected by the DMD dystrophic process. Knock-out models showed that TRIM32 is involved in ubiquitination of muscle cytoskeletal proteins as well as of protein inhibitor of activated STAT protein gamma (Piasγ) and N-myc downstream-regulated gene, two inhibitors of satellite cell proliferation and differentiation. Accordingly, we showed that in DMD/BMD muscle tissue, TRIM32 induction was more pronounced in regenerating myofibers rather than in necrotic muscle cells, thus pointing out a role of this protein in the regulation of human myoblast cell fate. This finding highlights TRIM32 as a possible therapeutic target to favor skeletal muscle regeneration in DMD patients.

Original languageEnglish
Pages (from-to)862-871
Number of pages10
JournalLaboratory Investigation
Volume96
Issue number8
DOIs
Publication statusPublished - Aug 1 2016

Fingerprint

Duchenne Muscular Dystrophy
Ligases
Ubiquitin
Muscles
Dystrophin
Proteasome Endopeptidase Complex
Protein Inhibitors of Activated STAT
Up-Regulation
Inbred mdx Mouse
Proteins
Proteasome Inhibitors
Cytoskeletal Proteins
Muscular Atrophy
Tripartite Motif Proteins
Muscle Proteins
Myoblasts
Poisons
Ubiquitination
Drug-Related Side Effects and Adverse Reactions
Muscle Cells

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)
  • Molecular Biology
  • Cell Biology

Cite this

The ubiquitin ligase tripartite-motif-protein 32 is induced in Duchenne muscular dystrophy. / Assereto, Stefania; Piccirillo, Rosanna; Baratto, Serena; Scudieri, Paolo; Fiorillo, Chiara; Massacesi, Manuela; Traverso, M.; Galietta, Luis Juan V; Bruno, Claudio; Minetti, Carlo; Zara, Federico; Gazzerro, Elisabetta.

In: Laboratory Investigation, Vol. 96, No. 8, 01.08.2016, p. 862-871.

Research output: Contribution to journalArticle

Assereto, Stefania ; Piccirillo, Rosanna ; Baratto, Serena ; Scudieri, Paolo ; Fiorillo, Chiara ; Massacesi, Manuela ; Traverso, M. ; Galietta, Luis Juan V ; Bruno, Claudio ; Minetti, Carlo ; Zara, Federico ; Gazzerro, Elisabetta. / The ubiquitin ligase tripartite-motif-protein 32 is induced in Duchenne muscular dystrophy. In: Laboratory Investigation. 2016 ; Vol. 96, No. 8. pp. 862-871.
@article{24f3fcc2a4944ec5b1c6de4b69efb183,
title = "The ubiquitin ligase tripartite-motif-protein 32 is induced in Duchenne muscular dystrophy",
abstract = "Activation of the proteasome pathway is one of the secondary processes of cell damage, which ultimately lead to muscle degeneration and necrosis in Duchenne muscular dystrophy (DMD). In mdx mice, the proteasome inhibitor bortezomib up-regulates the membrane expression of members of the dystrophin complex and reduces the inflammatory reaction. However, chronic inhibition of the 26S proteasome may be toxic, as indicated by the systemic side-effects caused by this drug. Therefore, we sought to determine the components of the ubiquitin-proteasome pathway that are specifically activated in human dystrophin-deficient muscles. The analysis of a cohort of patients with genetically determined DMD or Becker muscular dystrophy (BMD) unveiled a selective up-regulation of the ubiquitin ligase tripartite motif-containing protein 32 (TRIM32). The induction of TRIM32 was due to a transcriptional effect and it correlated with disease severity in BMD patients. In contrast, atrogin1 and muscle RING-finger protein-1 (MuRF-1), which are strongly increased in distinct types of muscular atrophy, were not affected by the DMD dystrophic process. Knock-out models showed that TRIM32 is involved in ubiquitination of muscle cytoskeletal proteins as well as of protein inhibitor of activated STAT protein gamma (Piasγ) and N-myc downstream-regulated gene, two inhibitors of satellite cell proliferation and differentiation. Accordingly, we showed that in DMD/BMD muscle tissue, TRIM32 induction was more pronounced in regenerating myofibers rather than in necrotic muscle cells, thus pointing out a role of this protein in the regulation of human myoblast cell fate. This finding highlights TRIM32 as a possible therapeutic target to favor skeletal muscle regeneration in DMD patients.",
author = "Stefania Assereto and Rosanna Piccirillo and Serena Baratto and Paolo Scudieri and Chiara Fiorillo and Manuela Massacesi and M. Traverso and Galietta, {Luis Juan V} and Claudio Bruno and Carlo Minetti and Federico Zara and Elisabetta Gazzerro",
year = "2016",
month = "8",
day = "1",
doi = "10.1038/labinvest.2016.63",
language = "English",
volume = "96",
pages = "862--871",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - The ubiquitin ligase tripartite-motif-protein 32 is induced in Duchenne muscular dystrophy

AU - Assereto, Stefania

AU - Piccirillo, Rosanna

AU - Baratto, Serena

AU - Scudieri, Paolo

AU - Fiorillo, Chiara

AU - Massacesi, Manuela

AU - Traverso, M.

AU - Galietta, Luis Juan V

AU - Bruno, Claudio

AU - Minetti, Carlo

AU - Zara, Federico

AU - Gazzerro, Elisabetta

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Activation of the proteasome pathway is one of the secondary processes of cell damage, which ultimately lead to muscle degeneration and necrosis in Duchenne muscular dystrophy (DMD). In mdx mice, the proteasome inhibitor bortezomib up-regulates the membrane expression of members of the dystrophin complex and reduces the inflammatory reaction. However, chronic inhibition of the 26S proteasome may be toxic, as indicated by the systemic side-effects caused by this drug. Therefore, we sought to determine the components of the ubiquitin-proteasome pathway that are specifically activated in human dystrophin-deficient muscles. The analysis of a cohort of patients with genetically determined DMD or Becker muscular dystrophy (BMD) unveiled a selective up-regulation of the ubiquitin ligase tripartite motif-containing protein 32 (TRIM32). The induction of TRIM32 was due to a transcriptional effect and it correlated with disease severity in BMD patients. In contrast, atrogin1 and muscle RING-finger protein-1 (MuRF-1), which are strongly increased in distinct types of muscular atrophy, were not affected by the DMD dystrophic process. Knock-out models showed that TRIM32 is involved in ubiquitination of muscle cytoskeletal proteins as well as of protein inhibitor of activated STAT protein gamma (Piasγ) and N-myc downstream-regulated gene, two inhibitors of satellite cell proliferation and differentiation. Accordingly, we showed that in DMD/BMD muscle tissue, TRIM32 induction was more pronounced in regenerating myofibers rather than in necrotic muscle cells, thus pointing out a role of this protein in the regulation of human myoblast cell fate. This finding highlights TRIM32 as a possible therapeutic target to favor skeletal muscle regeneration in DMD patients.

AB - Activation of the proteasome pathway is one of the secondary processes of cell damage, which ultimately lead to muscle degeneration and necrosis in Duchenne muscular dystrophy (DMD). In mdx mice, the proteasome inhibitor bortezomib up-regulates the membrane expression of members of the dystrophin complex and reduces the inflammatory reaction. However, chronic inhibition of the 26S proteasome may be toxic, as indicated by the systemic side-effects caused by this drug. Therefore, we sought to determine the components of the ubiquitin-proteasome pathway that are specifically activated in human dystrophin-deficient muscles. The analysis of a cohort of patients with genetically determined DMD or Becker muscular dystrophy (BMD) unveiled a selective up-regulation of the ubiquitin ligase tripartite motif-containing protein 32 (TRIM32). The induction of TRIM32 was due to a transcriptional effect and it correlated with disease severity in BMD patients. In contrast, atrogin1 and muscle RING-finger protein-1 (MuRF-1), which are strongly increased in distinct types of muscular atrophy, were not affected by the DMD dystrophic process. Knock-out models showed that TRIM32 is involved in ubiquitination of muscle cytoskeletal proteins as well as of protein inhibitor of activated STAT protein gamma (Piasγ) and N-myc downstream-regulated gene, two inhibitors of satellite cell proliferation and differentiation. Accordingly, we showed that in DMD/BMD muscle tissue, TRIM32 induction was more pronounced in regenerating myofibers rather than in necrotic muscle cells, thus pointing out a role of this protein in the regulation of human myoblast cell fate. This finding highlights TRIM32 as a possible therapeutic target to favor skeletal muscle regeneration in DMD patients.

UR - http://www.scopus.com/inward/record.url?scp=84979971117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979971117&partnerID=8YFLogxK

U2 - 10.1038/labinvest.2016.63

DO - 10.1038/labinvest.2016.63

M3 - Article

VL - 96

SP - 862

EP - 871

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 8

ER -